OmniAb, Inc. — Investor Relations & Filings

OmniAb, Inc. provides a technology platform for therapeutic antibody discovery, licensing its technologies to the pharmaceutical industry, biotechnology companies, and academic institutions. The company's core offering is a suite of proprietary and clinically validated transgenic animal platforms engineered to generate diverse repertoires of high-quality, fully human antibodies. A key technology is the Omni_dAb_ platform, which utilizes the first transgenic chicken to produce humanized single-domain antibodies, enabling recognition of highly conserved antigens. The platform is complemented by high-throughput screening technologies, such as the xPloration system, to facilitate the identification and development of next-generation therapeutics. OmniAb's modular and scalable solutions support partners throughout the drug discovery process.